As Norman “Ned” E. Sharpless, MD, prepares to become acting FDA commissioner in a few days, experts are divided in how he should address the explosion of e-cigarette use among minors and the devastating opioid epidemic whose tide has not turned.
He also faces the challenges of reinvigorating antibiotic development and lowering drug prices.
These areas were some of his predecessor, Scott Gottlieb, MD’s, main focus.
Though Sharpless has indicated elsewhere he would follow Gottlieb’s lead, it’s unclear if Sharpless will be the permanent nominee. Some have also